BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

771 related articles for article (PubMed ID: 36400097)

  • 1. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.
    Quek J; Chan KE; Wong ZY; Tan C; Tan B; Lim WH; Tan DJH; Tang ASP; Tay P; Xiao J; Yong JN; Zeng RW; Chew NWS; Nah B; Kulkarni A; Siddiqui MS; Dan YY; Wong VW; Sanyal AJ; Noureddin M; Muthiah M; Ng CH
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):20-30. PubMed ID: 36400097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A cross-sectional study on the prevalence rate and influencing factors of non-alcoholic fatty liver disease in overweight/obese children].
    Dai W; Yao ZZ; Ou-Yang SS; Xu NA; Zhou HX; Li XW; Zhong Y; Luo JY
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 May; 25(5):448-456. PubMed ID: 37272169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating future risk of NAFLD in adolescents: a prediction and decision curve analysis.
    Abeysekera KWM; Orr JG; Gordon FH; Howe LD; Hamilton-Shield J; Heron J; Hickman M
    BMC Gastroenterol; 2022 Jun; 22(1):323. PubMed ID: 35773644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
    Ye Q; Zou B; Yeo YH; Li J; Huang DQ; Wu Y; Yang H; Liu C; Kam LY; Tan XXE; Chien N; Trinh S; Henry L; Stave CD; Hosaka T; Cheung RC; Nguyen MH
    Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):739-752. PubMed ID: 32413340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis.
    En Li Cho E; Ang CZ; Quek J; Fu CE; Lim LKE; Heng ZEQ; Tan DJH; Lim WH; Yong JN; Zeng R; Chee D; Nah B; Lesmana CRA; Bwa AH; Win KM; Faulkner C; Aboona MB; Lim MC; Syn N; Kulkarni AV; Suzuki H; Takahashi H; Tamaki N; Wijarnpreecha K; Huang DQ; Muthiah M; Ng CH; Loomba R
    Gut; 2023 Nov; 72(11):2138-2148. PubMed ID: 37491159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
    Younossi ZM; Golabi P; de Avila L; Paik JM; Srishord M; Fukui N; Qiu Y; Burns L; Afendy A; Nader F
    J Hepatol; 2019 Oct; 71(4):793-801. PubMed ID: 31279902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD.
    Chakrabarty M; Jha AN; Sharma DJ
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
    Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
    Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of serum ferritin with non-alcoholic fatty liver disease: a meta-analysis.
    Du SX; Lu LL; Geng N; Victor DW; Chen LZ; Wang C; Yue HY; Xin YN; Xuan SY; Jin WW
    Lipids Health Dis; 2017 Dec; 16(1):228. PubMed ID: 29197393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes.
    Younossi Z; Aggarwal P; Shrestha I; Fernandes J; Johansen P; Augusto M; Nair S
    JHEP Rep; 2022 Sep; 4(9):100525. PubMed ID: 36039144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between MBOAT7 rs641738 polymorphism and non-alcoholic fatty liver in overweight or obese children.
    Zusi C; Morandi A; Maguolo A; Corradi M; Costantini S; Mosca A; Crudele A; Mantovani A; Alisi A; Miraglia Del Giudice E; Targher G; Maffeis C
    Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1548-1555. PubMed ID: 33810963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.
    Tan DJH; Ng CH; Lin SY; Pan XH; Tay P; Lim WH; Teng M; Syn N; Lim G; Yong JN; Quek J; Xiao J; Dan YY; Siddiqui MS; Sanyal AJ; Muthiah MD; Loomba R; Huang DQ
    Lancet Oncol; 2022 Apr; 23(4):521-530. PubMed ID: 35255263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Non-Alcoholic Liver Diseases: NAFLD, NASH, Fibrosis, Cirrhosis-A Systematic Review, Meta-Analysis and Meta-Regression.
    Gudan A; Jamioł-Milc D; Hawryłkowicz V; Skonieczna-Żydecka K; Stachowska E
    Nutrients; 2022 Dec; 14(24):. PubMed ID: 36558421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.
    Jarvis H; Craig D; Barker R; Spiers G; Stow D; Anstee QM; Hanratty B
    PLoS Med; 2020 Apr; 17(4):e1003100. PubMed ID: 32353039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of biopsy proven non-alcoholic fatty liver disease in healthy non-obese and lean population of living liver donors: The impact of uric acid.
    Eshraghian A; Nikeghbalian S; Geramizadeh B; Kazemi K; Shamsaeefar A; Malek-Hosseini SA
    Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):572-578. PubMed ID: 31611031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
    Lin CL; Tai CM; Huang JF; Liu CJ; Chen HF; Cheng PN; Chen CY; Peng CY; Wang CC; Weng SH; Tseng TC; Kao JH
    J Gastroenterol Hepatol; 2022 Oct; 37(10):1901-1910. PubMed ID: 35790343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults.
    Liu J; Ayada I; Zhang X; Wang L; Li Y; Wen T; Ma Z; Bruno MJ; de Knegt RJ; Cao W; Peppelenbosch MP; Ghanbari M; Li Z; Pan Q
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e573-e582. PubMed ID: 33618024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of different insulin resistance indices in assessment of non-alcoholic fatty liver disease in overweight/obese children.
    El-Karaksy HM; El-Raziky MS; Fouad HM; Anwar GM; El-Mougy FM; El-Koofy NM; El-Hennawy AM
    Diabetes Metab Syndr; 2015; 9(2):114-9. PubMed ID: 25470627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Non-alcoholic Fatty Liver Disease in India: A Systematic Review and Meta-analysis.
    Shalimar ; Elhence A; Bansal B; Gupta H; Anand A; Singh TP; Goel A
    J Clin Exp Hepatol; 2022; 12(3):818-829. PubMed ID: 35677499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.